Qingdao Vland Biotech Inc

Qingdao Vland Biotech Inc has a market capitalization of 3.31 billion CNY and a price-to-earnings ratio of 52.88, indicating a relatively high valuation compared to its earnings. The company's price-to-book ratio is 1.91, suggesting that the market values the company at a premium to its book value. The enterprise value to EBITDA ratio is 32.06, and the enterprise value to revenue ratio is 3.01, both of which are metrics commonly used in the biotechnology industry to assess valuation.

The company's profitability is modest, with a return on equity of 3.6% and a return on assets of 2.1%. These figures are below the typical performance benchmarks for the biotechnology industry, which often prioritize long-term growth over immediate profitability. The gross profit margin is 44.8%, and the operating margin is 9.4%, indicating that the company is able to maintain relatively healthy margins despite the high R&D costs typical in the sector.

Qingdao Vland Biotech Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's total revenue for the latest period is 1.32 billion CNY, with no information provided on the geographic distribution of this revenue. This lack of geographic diversification could pose a risk if the company's primary market experiences economic or regulatory challenges.

The company's growth trajectory is modest, with no specific growth rates provided in the latest financial data. The capital expenditure for the period is negative, indicating that the company is generating more cash from operations than it is spending on capital investments. This could suggest a focus on maintaining current operations rather than expanding capacity or entering new markets.

The company's liquidity position is characterized as medium risk, with a current ratio of 1.04 and a debt-to-equity ratio of 0.38. The company has a long-term debt of 664.6 million CNY, and its free cash flow is 43.2 million CNY, which is insufficient to cover the long-term debt in the short term. The risk assessment indicates that the company has a low dilution risk, but the net cash position is negative after subtracting total debt, which could affect its ability to fund operations without external financing.

Recent events and filings do not provide specific details on the company's strategic initiatives or major developments. The latest actual EPS is 0.25 CNY, and the latest actual revenue is 1.32 billion CNY, which aligns with the company's reported financial performance. There are no disclosed recent events that would significantly impact the company's operations or financial position.